INmune Bio Enters Strategic Commercialization Agreement with Uniphar

INmune Bio, Inc. has entered into a strategic commercialization agreement with Uniphar to create a global framework for its Ebstrocel™ therapy. The partnership will initially target named-patient access in select European and MENA markets, aiming to establish a capital-efficient foundation for broader commercialization efforts.